A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Clinical trial NCT00516802 · COMPLETED

Trial details

NCT number: NCT00516802
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Neoplasms

Start date: 2007-01-01
Primary completion: 2009-01-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.